摘要
铁在生物体起重要作用,铁吸收、储存、转运过程均受到精密的调控。铁调素(hepcidin,Hepc)是由肝脏产生的肽类激素,可以下调铁输出蛋白——膜铁转运蛋白(ferroportin,FPN),从而抑制肠道铁吸收和储铁器官铁释放,负性调控铁稳态的平衡。除肝脏外,其他器官也可表达少量铁调素,铁调素的表达受铁储量、红细胞生成活性、炎症、缺氧、内质网应激、甾体类激素等调节。铁调素过少可引起铁过载类疾病,铁调素过多可导致铁利用障碍性贫血、炎症性贫血等疾病。目前以铁调素为靶点的药物开发已经成为铁代谢研究领域的焦点和热点问题,一系列铁调素激动剂或拮抗剂类药物已经从实验室进入临床测试。文中主要论述铁调素在机体铁稳态中的作用,以及以铁调素为靶点的药物开发所取得的进展。
Iron plays an important role in organisms,and iron absorption,storage and transport are precisely regulated.Hepcidin（Hepc）,a peptide hormone produced by the liver,is the only recognized iron output protein so far.Hepcidin acts as a negative iron homeostasis regulator,which is able to inhibits the activity of ferroportin and thus inhibiting iron absorption in the intestine and iron release from iron storage organs.In addition to the liver,other organs also express a small amount of hepcidin.The expression of hepcidin is regulated by iron storage,erythropoietic activity,inflammation,hypoxia,endoplasmic reticulum stress and steroid hormones.Reduced expression of hepcidin would cause iron overload diseases,while elevated expression of hepcidin would lead to inflammatory or iron restricted anemia.At present,the development of drugs targeting hepcidin has become a focus issue in iron metabolism field.A series of hepcidin agonists or antagonists have entered clinical trials from the laboratory.This review mainly discusses the function of hepcidin in iron homeostasis and the progress of drugs development that targeting hepcidin.
作者
赵晋英
李艳伟
ZHAO Jinying;LI Yanwei(School of Laboratory Medicine,Shaoyang University,Shaoyang 422000,China;The Key Laboratory of Molecular Biology Diagnosis,Shaoyang University,Shaoyang 422000,China;School of Clinical Medicine,Shaoyang University,Shaoyang 422000,China)
出处
《邵阳学院学报（自然科学版）》
2018年第5期78-92,共15页
Journal of Shaoyang University：Natural Science Edition
基金
湖南省教育厅科研项目(16C1439)
